Small and medium pharmaceutical companies are appealing to the health minister, raising concerns about stringent manufacturing standards imposed by the central drug regulatory body. These associations fear that the abrupt implementation timeline will force many MSMEs to shut down due to financial constraints and inability to meet the new requirements, potentially leading to medicine shortages.